|
|
|
|
|
Sulfasalazine
drug data and news
Sulfasalazine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Sulfasalazine | ||
| Brand Names/Synonyms | Accucol; Alti-Sulfasalazine; Asulfidine; Azlufidine En-Tabs; Azopyrin; Azopyrine; Azulfidine; Azulfidine En-Tabs; Benzosulfa; Colo-Pleon; Pms-Sulfasalazine; Pms-Sulfasalazine E.C.; Reupirin; Rorasul; S.A.S. 500; S.A.S. Enteric-500; S.A.S.-500; Salazopiridazin; Salazopyridin; Salazopyrin; Salazopyrin En-Tabs; Salazosulfapyridin; Salazosulfapyridine; Salicylazosulfapyridine; Salisulf; Sulcolon; Sulfasalazin; Sulfasalazine; Sulphasalazine; W-T Sasp Oral | ||
| Indication | For the treatment of Crohn's Disease and Rheumatoid Arthritis as a second-line agent | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis. | ||
| Mechanism Of Action | The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. | ||
| Sulfasalazine News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antirheumatic Agents; Gastrointestinal Agents; Anti-inflammatory Agents; Anti-Infectives; Sulfonamides; ATC:A07EC01 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Sulfasalazine: Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered. Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies. The overall toxicity profile of the combination revealed an increased incidence of gastrointestinal adverse events, especially nausea, when compared to the incidence associated with either drug administered alone. Drug/Laboratory Test Interactions: The presence of sulfasalazine or its metabolites in body fluids has not been reported to interfere with laboratory test procedures. REFERENCES 7.Farr M, et al. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis. British Jnl Rheum 1991;30:413-417. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | 2-hydroxy-5-[4-(pyridin-2-ylsulfamoyl)phenyl]azo-benzoicacid | ||
| Chemical Formula | C18H14N4O5S | ||
| Molecular Weight | 398.394 g/mol | ||
| Smiles String | C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O | ||
| Melting Point | 220 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.752 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 5-10 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Sulfasalazine.html http://www.rxlist.com/cgi/generic/sulfasal.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00152 | ||
| CAS Registry Number | 599-79-1 | ||
| KEGG Compound ID | C07316 | ||
| PubChem ID | SID:9524 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 685933 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |